B-cell leukemia/lymphoma-2-associated death promoter homolog (Bad) is a switchable protein of the mitochondria apoptotic pathway. Drug treatment and multiple endogenous signals usually change its phosphorylation status in several specific sites and modify its biological configuration by cleaving into truncated forms so as to accomplish a down-stream regulation of pro-apoptotic or pro-survival signaling pathways in glioma cells. Bad can also mediate the pro-apoptotic effects of cyclins to ensure a consistency of the apoptotic procedures and the cell cycle arrest. Bad protein has been recognized as an important therapeutic target for various anti-glioma drugs and an ideal candidate for gene therapy.